• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
Trade NameVITALITY DS ICD SYSTEMS
Classification Nameprogrammer, pacemaker
Generic Namecardiac resynchronization therapy defibrillator (crt-d) system
Regulation Number870.3700
ApplicantGUIDANT CORP.
PMA NumberP960040
Supplement NumberS031
Date Received03/17/2003
Decision Date07/10/2003
Product Code
KRG[ Registered Establishments with KRG ]
Advisory Committee Cardiovascular
Supplement Typenormal 180 day track
Supplement Reason change design/components/specifications - other
Expedited Review Granted? No
Combination Product No
Recalls CDRH Recalls
Approval Order Statement 
Approval for the vitality ds vr model t135, vitality ds model t125, and vitality el model t127 implantable cardioverter defibrillator systems and the programmer software application model 2844 version 3. 6. The device, as modified, will be marketed under the trade name vitality ds vr model t135, vitality ds model t125, and vitality el model t127 implantable cardioverter defibrillator systems and the programmer software application model 2844 version 3. 6, and the indication for use is as follows: guidant icds are intended to provide therapy for the automated treatment of life threatening ventricular arrhythmias. Patient populations who are indicated for a guidant icd include 1) those who have had spontaneous and/or inducible life-threatening ventricular arrhythmias and those who are at high risk for developing such arrhythmias, or 2) patients who may benefit from prophylactic treatment due to a prior myocardial infarction and an ejection fraction of <=30% (as defined in appendix e ).
-
-